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In regard to cancer therapy, magnetoelectric nanoparticles (MENs) have proven to be in a class of its
own when compared to any other nanoparticle type. Like conventional magnetic nanoparticles, they
can be used for externally controlled drug delivery via application of a magnetic field gradient and
image-guided delivery. However, unlike conventional nanoparticles, due to the presence of a nonzero magnetoelectric effect, MENs provide a unique mix of important properties to address key challenges in modern cancer therapy: (i) a targeting mechanism driven by a physical force rather than
antibody matching, (ii) a high-specificity delivery to enhance the cellular uptake of therapeutic drugs
across the cancer cell membranes only, while sparing normal cells, (iii) an externally controlled
mechanism to release drugs on demand, and (iv) a capability for image guided precision medicine.
These properties separate MEN-based targeted delivery from traditional biotechnology approaches
and lay a foundation for the complementary approach of technobiology. The biotechnology approach
stems from the underlying biology and exploits bioinformatics to find the right therapy. In contrast,
the technobiology approach is geared towards using the physics of molecular-level interactions
between cells and nanoparticles to treat cancer at the most fundamental level and thus can be
extended to all the cancers. This paper gives an overview of the current state of the art and presents
an ab initio model to describe the underlying mechanisms of cancer treatment with MENs from the
C 2017 Author(s). All article content, except where otherwise noted, is
perspective of basic physics. V
licensed under a Creative Commons Attribution (CC BY) license (http://creativecommons.org/
licenses/by/4.0/). [http://dx.doi.org/10.1063/1.4978642]
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I. INTRODUCTION

Achieving adequately high specificity to target cancer
cells while sparing normal cells remains one of the greatest
challenges in cancer therapy to date.1–3 Ongoing research has
attempted to address this fundamental challenge by using
nanoparticles as targeted delivery vehicles. Due to their small
sizes and unique shapes, nanoparticles can help steer a therapeutic load to specific targets and meet a wide range of
requirements for overcoming numerous biological barriers.4–10
There are endless types of nanoparticle delivery systems, both
passive and active, constantly being developed. Passive systems mostly rely on exploiting the enhanced permeability and
retention (EPR) effect, which exists due to the high leakiness
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of tumor blood vessels and the lack of a lymphatic system for
drainage.11–14 The delivery specificity can be further improved
by adding an active delivery mechanism, for example, through
conjugating nanoparticles with monoclonal antibodies (mAbs)
tailored to recognize over-expressed tumor-specific biomarkers.15–21 In addition, nanoparticles must be able not only
to provide high-specificity targeted delivery but also to ensure
that the therapeutic load is not prematurely released in the
plasma or interstitial space before it reaches the intended target.22–25 Therefore, nanoparticles have been further functionalized to control drug release by externally applied
temperature,26,27 ultrasound,28,29 intracellular pH level,30 intracellular enzymes,31 or magnetic fields.32–35 Nevertheless, all
these approaches still have inadequately low efficacy.
In parallel, there has been a focus on using the phenomenon of electroporation for enabling a high-efficacy high-specificity cellular uptake of a drug.36–43 In this case, an electric
field above a cell-specific threshold causes a dielectric breakdown of the cell membrane.44 This breakdown field is different for cancer and normal cells of the same type. For example,
application of an electric field on the order of 1 kV/cm can
create sufficiently large pores allowing for an enhanced cellular uptake of molecules by cancer cells while it takes a factor
of two or five higher field to achieve this effect in the normal
cells. Although very promising, the electroporation involves
relatively high electric fields at a relatively large scale and
thus comes with a collateral damage.
Based on an analysis of recent studies,45–49 combined
with a new study on using liquid-environment atomic force
microscopy (AFM) to study the interaction between nanoparticles and the cellular membranes, this paper presents a basic
physics model to help understand how a class of multiferroic
nanoparticles known as magnetoelectric nanoparticles
(MENs) could address the above challenges.50–53 Indeed,
MENs provide (a) a targeting mechanism driven by a physical force rather than antibody matching, (b) a delivery mechanism that enhances cellular uptake of a therapeutic load
across the cancer cell membranes only, without affecting
normal cells, (c) an externally controlled mechanism that
releases the load on demand, last but not least (d) due to the
presence of a magnetic moment, they can be used for imageguided therapy. With the above said, MENs present a novel
platform to treat cancer not from the perspective of bioinformatics but rather from the perspective of the molecular-level
physics of the interaction between nanoparticles and cellular
microenvironment. Such an approach, hereinafter referred to
as technobiology, is complementary to the traditional biotechnology approach.
II. UNDERLYING PHYSICS
A. Difference between MENs and magnetic
nanoparticles (MNPs)

MENs must not be confused with traditional magnetic
nanoparticles (MNPs), e.g., superparamagnetic iron oxide
nanoparticles (SPIONs)54–57 or other superparamagnetic and
non-superparamagnetic ferromagnetic or ferrimagnetic nanostructures used for targeted delivery or magnetic imaging.58–61 Like MNPs, MENs have a non-zero magnetic
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moment and therefore can be transported via application of
an external d.c. magnetic field with a non-zero spatial gradient. Also, the negative feedback loop required for imageguided navigation can be closed through existing magnetic
imaging techniques such as magnetic resonance imaging
(MRI) or magnetic particle imaging (MPI).62–64 However,
unlike MNPs, MENs offer a novel functionality—an energyefficient control of intrinsic electric fields in close proximity
to the nanoparticles via application of external d.c. and a.c.
magnetic fields. Due to the magnetoelectric effect (ME)
effect, MENs allow an external control of the electric fields
that underlie the intrinsic molecular interactions between
specific cells and the drug-loaded nanoparticles as well as
the interaction between MENs and the loaded drug. An
immediate consequence of this capability is the freedom to
engineer an adequately strong bond between the nanoparticles and the drug to avoid an undesired release of the therapeutic load before it reaches the target; only when an a.c.
magnetic field is applied, this strong bond is “turned off” on
demand. This mechanism of using an a.c. field to controllably break the bond between MENs and the load has been previously described with regard to the topic of delivery of
antiretroviral therapy across the blood-brain barrier (BBB) to
treat HIV-1 virus hidden deep in the brain.65 In addition, due
to the ME effect, using MENs opens a pathway to exploit
intrinsic electric properties of the cell membrane at the nanoscale for enabling targeted high-specificity delivery without
relying on any bioactive mechanism. The cell membrane,
consisting of numerous ion channels, is an electrically polarizable medium, and its electric charge strongly depends on
the cellular microenvironment, e.g., its pH level. As a result,
cellular properties can be significantly and differently (for
normal and cancer cells) affected by local electric fields.66,67
This difference is the basis for using electroporation for
inducing a high-specificity drug uptake by cancer cells.
According to the conventional approach to an
electroporation-based cancer treatment, a relatively large
electric field, on the order of 1000 V/cm, is applied at the
macroscale, which inevitably results in undesired side
effects. With MENs, this property of electroporation can be
scaled down to the nanoscale. As a result, the MEN-induced
electroporation, hereinafter referred to as nanoelectroporation, would result in significantly reduced side effects
because the relatively high field is limited to the nanoscale
region in proximity to each nanoparticle. In addition, the specificity factor (SF), defined as the ratio of the average number of nanoparticles penetrated into a cancer cell versus the
average number of nanoparticles penetrated into an adjacent
normal cell under equivalent conditions, can be significantly
increased in the case of the nanoelectroporation, as discussed
below in more detail. Due to this nanoelectroporation ability,
MENs not only further improve the specificity of the EPRbased delivery but also add another targeting mechanism to
enable passive delivery at the intracellular level and thus
pave a way to treatment of both primary and secondary
tumors at different cancer progression levels. Last but not
least, because of the fundamental nature of this externally
controlled approach, MENs can be used to treat all kinds of
cancers including fast-progressing brain tumors and other
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solid and liquid tumors. Brachytherapy would be one example
of a current approach which could be completely replaced by
MENs. Brachytherapy uses a sealed radioactive pellet, e.g.,
made of iridium, placed close to a tumor site through catheters.72 When activated, the pellet emits radiation which kills
both cancer and normal cells a few millimetres away. Using
field-activated MENs instead of the strongly radioactive pellet
can significantly improve the specificity of the treatment and
thus reduce or eliminate side effects.
B. Synthesis and characterization of MENs

MENs can be synthesized according to standard chemical procedures described in previous studies. One of the
most popular room-temperature configurations is the coreshell nanostructure made of a magnetostrictive core, e.g.,
CoFe2O4, and a piezoelectric shell, e.g., BaTiO3.68–71 By
default, in this paper, the average size of MENs is approximately 30 nm and the average size of the core is approximately 10 nm. X-Ray diffraction (XRD) measurements have
confirmed the cubic and tetragonal crystal structures of the
core and shell, respectively. Depending on a specific application, whether it is for a drug delivery, a neural stimulation, or
3D navigation and/or imaging, MENs can be further coated
with thin functionalization layers serving as linkers to the
therapeutic load or to enable hydrophilic or hydrophobic surface suitable for the microenvironment of interest. The ME
coefficient, a, for these nanostructures is known to be in a
range from 10 to over 100 mV cm1 Oe1, depending on the
phase compositions and the quality of the interface between
the core and the shell. The saturation magnetization of these
particular MENs is on the order of 10 emu/g, which is an
order of magnitude smaller than that for high-moment iron
oxide nanoparticles. Considering the core is made of a relatively high anisotropy structure, these MENs are not superparamagnetic and have a room temperature coercivity on the
order of 100 Oe. On a final note, it is worth noting that in
general MENs are not limited to this particular composition.
There are many other compositions which display a non-zero
ME effect. Furthermore, it is likely that in the future MENs
will be made of biodegradable organic materials; for example, carbon based nanostructures have already been shown to
display a non-zero ME effect.73
C. Targeting by MENs

In general, there are two fundamentally different
approaches to targeting with MENs, using local and systemic
administration of nanoparticles, respectively. For the local
administration, MENs could be either directly injected into a
tumor site or navigated to the target site via application of
localized magnetic fields after the nanoparticles are administrated in the vasculature. For example, it has been shown that
using MRI-guided navigation with a pulsed sequence of field
gradients, magnetic nanoparticles could be localized at any
point in a 3D space with a spatial precision of less than
0.1 mm.74 For the systemic administration, MENs could be
administrated intravenously. In either case, the delivery and
uptake specificity could be further significantly improved
due to the following physics.
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Unlike purely active delivery approaches, e.g., using
mAbs, T-cells (CAR T-Cell), or cancer vaccines, MENs
offer a passive delivery mechanism, which is complementary
to the well-known EPR effect.75 The EPR effect ensures
delivery of drug-loaded nanoparticles into relatively large
tumor aggregates but not in relatively small aggregates made
of one or few cancer cells. In contrast, due to a different
underlying physics, MENs-driven targeting works equally
well with cell aggregates and individual cells. Because
MENs generate their own electric fields, which in turn can
be controlled by external magnetic fields, they can specifically electroporate cancer cells without affecting surrounding normal cells, as described below in more detail. In this
case, the localization range of the nanoparticle-generated
electric field is defined by the nanoparticle’s average size,
which is approximately 30 nm. In turn, this localization
range is orders of magnitude smaller than the characteristic
cell size, which is on the order of a few microns. Therefore,
MENs could be used to target primary and metastasized cancer cells even at a very early stage of cancer progression.
Last but not least, because of the existence of an externally
controlled surface charge, MENs bring another dimension to
targeted delivery; not only can they increase the specificity
factor but also can provide new functions of externally controlled cancer cell penetration and drug release via application of external magnetic fields. In a trivial approximation,
the electric field generated by a MEN at a point on the cell
membrane consists of two terms:
E¼k

3ðp  ^r Þ^r  p kQ
þ 2 ^r ;
r3
r

(1)

where k is the Coulomb constant, Q and p are the MEN’s
electric charge and dipole moment, respectively, and r is the
distance between the nanoparticle and the observation point
on the membrane. The first term is determined by the
magnetic-field dependent electric dipole moment due to the
ME effect, p ¼ aH, where a is the ME coefficient and H is
the external magnetic field. The second term is determined
by the surface electric charge which is formed according to
the colloidal chemistry when MENs are placed in a solution,
e.g., the blood or the lymph. In this case, a double charged
layer is formed around the nanoparticle’s surface because of
the interplay of chemical and electrical forces. The surface
charge can be determined by measuring Zeta potential.
Furthermore, previously it has been shown that this surface
charge can be further increased with an external magnetic
field increase; in other words, the field dependence of the
surface charge also depends on the ME effect. It can be noted
that the surface charge term has a more significant effect
because it drops with a distance substantially slower (1/r2)
compared to the dipole charge term (1/r3).
Because both MENs and the cell membranes have the
same charge polarity, MENs can easily go through a capillary without being engulfed by the surrounding cells.
However, when MENs are in close proximity to the cell
membranes (within a distance on the order of a micron), their
electric field (on the order of 0.1 V/lm, as shown below
mostly due to the charge) is sufficiently strong to induce a
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FIG. 1. Illustration of the dependence
of the cutoff distance, rc, on application of an external d.c. magnetic field,
H. (a) The nanoparticles within this
distance from the membrane surface
target the cancer cells due to the highspecificity nanoelectroporation effect.
(b) The distance is increased with an
increase in the magnetic field.

local dielectric breakdown in the cancer cells but not too
strong (ⱗ1.5 V/lm) where it may cause this effect in the normal cells. This dielectric breakdown is reflected in a local
change of the lipid bilayer of the cellular membrane. Such a
field-dependent local change leads to cellular uptake of the
drug-loaded nanoparticles through the membrane surface.
Indeed, it is known that the conductivity of the intermediate
cancer cell membrane is by three orders of magnitude larger
than that of the normal cell membrane.77 The highconductivity membrane induces a local attraction force
between MENs and the cancer cell due to the electrostatic
“mirror” effect. Here, it is worth noting that this nanoelectroporation effect could be further increased through application
of a pulsed magnetic field sequence. In this case, the intermediate high-conductivity breakdown state effectively lasts longer and thus the efficacy of this treatment is significantly
increased. That is the reason why the a.c. field application
might be more effective compared to the d.c. field application.
However, to simplify the explanation, the following description is focused on the d.c. case. In a first order approximation,
there are two distinct states of the membrane. In its normal
state, the membrane is non-conducting. In this case, the negatively charged MENs are pushed away from the negatively
charged membrane surface. On the contrary, during the intermediate nanoelectroporation process, the membrane surface
of the cancer cells is conducting and thus MENs are attracted
to the cancer cells. According to the “mirror image” model,
the attraction force could be estimated with this expression,
Fmirror ¼ kQ2 =4r2 ;

(2)

where the factor 1=4 is due to the fact that the effective distance
between the real and image charges is 2r, while r is the distance between the nanoparticle and the membrane surface.
Furthermore, as previously shown, the effective surface
charge and thus this attraction force can be further increased
with an increase in the externally applied magnetic field. This
magnetic field dependence of the charge can be found through
an experimental measurement of Zeta potential, V(H), in a
phosphate buffer solution (PBS) with a pH level similar to
that in the blood, Q ¼ V(H)d/k. Now, it is possible to estimate
the cut-off distance between the nanoparticle and the membrane surface, rC, below which the electric field would be
above the nanoelectroporation threshold on the order of 0.1 V/
lm for the cancer cells: rC ¼ 0.5(kQ/E)1/2. For example, it has
been shown that application of a magnetic field on the order
of 300 Oe could increase the cut-off distance by a factor of

two. Such an increase would significantly increase the number
of the nanoparticles capable of triggering local nanoelectroporation and consequently would significantly increase the specificity factor of targeted delivery. This concept of MENbased targeting is illustrated in Figure 1. It could be noted that
this overly simplified theory does not take into account the
laminar flow in the circulation.
D. Drug release on demand

After the drug-loaded MENs enter the cancer cells, the
drug can be released off the nanoparticles on demand via
application of an a.c. external magnetic field. In this case, as
previously shown, even a relatively small magnitude a.c.
field (ⱗ50 Oe) in the near-d.c. frequency ranging from 10 to
over 100 Hz is sufficiently strong to release substantial
amount of the drug into the cancer cells. It has been hypothesised that application of an a.c. field “shakes” the drug off
the nanoparticles by significantly weakening the electricfield bond which holds the two together, as illustrated in Fig.
2. According to the trivial model, the electric dipole moment
induced by an external magnetic field due to the ME effect is
DP ¼ aH; therefore, the displaced surface charge density on
the diametrically opposite side of the nanoparticle would be
rME  6aH. In other words, the magnetically triggered electric dipole moment breaks the symmetry of ionic bonds
around the nanoparticle. To a zeroth approximation, when
the displaced surface charge is comparable to the charge
involved in an original bond, rME  Qionic/pd2, the bond can
be broken. Then, the threshold magnetic field amplitude to
break a bond can be evaluated according to this simple
expression:
Hth  Qionic =pd2 a;

(3)

FIG. 2. Illustration of the drug release mechanism via application of an a.c.
magnetic field.
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FIG. 3. Illustration of a fieldcontrolled targeted drug (PTX) delivery and release by MENs.

where d is the diameter of the nanoparticle, a is the ME coefficient, and Qionic is the displaced charge in the ionic bond.
Application of an a.c. field would break the bonds in all the
orientations around the nanoparticle.
Here, it is worth reminding that it is imperative to
release the drug off MENs to increase the drug bioactivity
only after the drug-loaded MENs penetrate the cancer
cells.76 In other words, MENs enable a drug retention control
via application of external magnetic fields; the initial step of
high-specificity cellular penetration and the final step of drug
release off MENs are triggered via application of d.c. and
a.c. fields, respectively.
In summary, the above described three-step field-controlled process for targeted drug delivery and release, respectively, is illustrated in Fig. 3.
III. SUPPORTING EXPERIMENTS
A. Confocal microscopy study of high-specificity
cellular penetration

The purpose of the first described in vitro experiment was
to show how an external d.c. magnetic could be used to induce
a penetration of drug-loaded MENs into cancer cells. A popular mitotic inhibitor paclitaxel (PTX) was used as the therapeutic load. In the described microscopy experiments, the PTX’s
fluorescent version known as Flutax-2 was imaged at 488 nm
(green color). A multidrug resistant cancer cell line MES-SA/
DX5 was used to test the field-induced penetration. For comparison, similar images were taken for two other cases with
cells incubated under equivalent conditions without any drug
and just with the drug, respectively. Microscopy images of the

two control cases and the cells incubated with MENs without
and with exposure to a d.c. field of 30 Oe for approximately 12
h are shown in Figs. 4(a)–4(d), respectively. The optically
measured percentages of the drug uptake per mg of protein in
the four cases were 0, less than 0.3%, less than 0.2%, and
more than 6%, respectively. According to the procedures of
the experiment, the green light could be seen only from the
drug coming from inside the cells, because all the extracellular
material was washed away. The experiment clearly showed a
strong field dependence of the cellular uptake of the drugloaded MENs. Indeed, the uptake of the drug increased from
less than 0.2% to over 6%, i.e., by a factor of 30, after application of a relatively small d.c. field of 30 Oe.
Another experiment was conducted to demonstrate a highspecificity cellular uptake with MEN-based delivery on ovarian cancer and normal cell lines SKOV-3 and HOMEC,
respectively. The optically measured drug uptake depending
on the applied d.c. magnetic field for cancer and normal cells
is shown in Fig. 5. Indeed, it could be observed that there was
a significant field range, from 50 Oe to 500 Oe, when visibly large amount of the drug penetrated the cancer cells while
barely any drug penetrated the normal cells. As mentioned earlier, the effect of nanoelectroporation could be further
increased via application of a periodic sequence of magnetic
field pulses to effectively prolong the membrane’s intermediate
dielectric breakdown state which leads to the nanoparticles’
cellular uptake. Application of an a.c. magnetic field partially
mimics this pulsed sequence effect.53 Indeed, this a.c. field
dependence was demonstrated in the same experimental study.
Another experiment which demonstrated the fielddependent cellular penetration of MENs was conducted with

FIG. 4. Confocal microscopy imaging of the uptake of Flutax-2 by cell line MES-SA/DX5 for four different drug-delivery-system combinations: (a) no drug,
(b) free Flutax-2 (drug uptake per mg of protein: <0.3%), (c) MENs loaded with Flutax-2 with no field (<0.2%), and (d) MENs loaded with Flutax-2 in a
30 Oe d.c. field (>6%). The scale bar is approximately 50 um.
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C. Liquid-environment atomic force microscopy study
of the nanoparticle-cell interaction

FIG. 5. Optically measured (with a fluorometer) field dependence of the
drug uptake per mg of protein for cancer and normal cell lines SKOV-3 and
HOMEC, respectively.

atomic force microscopy (AFM) and magnetic force microscopy (MFM) imaging of cell lysates. This experiment
directly confirmed the presence of MENs inside cancer cells
only after application of a 100-Oe d.c. field.
B. Drug release off MENs via application of an a.c.
field

The purpose of the following experiments was to prove
that the therapeutic load could be released off MENs via
application of an a.c. magnetic field. Consequently, the function of the drug release could be physically separated from
the function of high-specificity targeting, in turn, achieved
via application of a d.c. field.
In one experiment, the amount of the released drug (paclitaxel) was measured spectrophotometrically at its maximum absorption wavelength of approximately 230 nm. It is
known that the bioactivity of the drug significantly increases
after the release due to the increased “free” surface area. The
dependence of the released drug on the strength and frequency of the a.c. field ranging from 12 to 66 Oe and 0 to
1000 Hz, respectively, for different application times ranging
from 1 min to 2 h, is shown in a chart in Fig. 6.
Other experiments to confirm the drug release via
application of an a.c. field were based on Fourier-transform
infrared (FTIR) spectroscopy and X-ray diffraction (XRD)
measurements.

FIG. 6. The dependence of the release of the drug, paclitaxel, on the a.c.
field strength and frequency for five different application times: 1, 5, 10, 60,
and 120 min. The data were measured spectrophotometrically as the absorbance at 230 nm wavelength.

A liquid environment atomic force microscopy (AFM)
study was conducted with the goal to directly measure the
surface of cancer and normal cells under different experimental conditions. In the following experiment, glioblastoma
(U87-MG) and endothelial cells were used as the cancer and
normal cells, respectively. Glioblastomas represent the most
frequent primary brain tumors while endothelial cells are
characteristic normal brain cells. It was already demonstrated
that drug-loaded MENs could be navigated across the bloodbrain barrier (BBB) via application of a sufficiently strong
d.c. magnetic field gradient (on the order of 1000 Oe/cm)
with the subsequent controlled release of the drug after the
nanoparticles are placed deep in the brain.65 Typical AFM
images of endothelial and glioblastoma cells are shown in
Figs. 7(a) and 7(b), respectively. It can be noted that the normal cells have a more continuous surface morphology compared to the cancer cells with clearly visible striations with a
characteristic size on the order of 100 nm.
Another AFM experiment was conducted to understand how MENs penetrated the cancer cells. MENs were
added into media with glioblastoma cells through a special
Multimode liquid environment microprobe container.
Here, it is worth noting that usually when nanoparticles or
other nanoscale foreign reagents get attached to the membrane surface, they quite rapidly (within seconds) move
across the membrane and penetrate the cell. The exact origin of this process still remains an open question; it might

FIG. 7. AFM image pair (z height and phase (right)) for (a) endothelial and
(b) glioblastoma cells.
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be defined either by a chain signalling between biomolecules within the cell or by some electric field effects in the
membrane and the cellular plasma or a combination of
these two effects. It is not trivial to use AFM to observe
the fast dynamic of the nanoparticle-cell interaction. To
slow down the cellular uptake of the nanoparticles, this
experiment was conducted at a relatively high concentration of MENs to ensure the cells are saturated and as a
result the nanoparticles become visible on the membrane
surface. An important observation of this experiment was
the fact that the nanoparticles preferred to penetrate the
cancer cell through the striations in the cellular membrane,
as shown in Fig. 8.
Last but not least, it could be mentioned that MENs
operate at relatively low fields and frequencies and thus do
not cause significant heating effects, as was confirmed
through infrared measurements of the cell surface at different
concentrations of MENs under different field exposures.
IV. CONCLUSION

The discussed experiments have demonstrated that
MENs could be used for externally controlled targeted drug
delivery and release. Furthermore, these two important functions, i.e., delivery and release, could be physically separated
via application of d.c. and a.c. external magnetic fields,
respectively, as indicated by the hypothesised theory and
confirmed by a number of independent experiments. For
example, confocal microscopy studies have directly confirmed that the penetration of MENs into cancer cells occurs
only after the application of a d.c. magnetic field on the order
100 Oe, while numerous spectrophotometry measurements
have shown that the drug is released off the nanoparticles
only after the application of an a.c. magnetic field with a
strength on the order of 50 Oe and a near-d.c. frequency of
100 Hz. As for the high-specificity delivery, one of the most
important characteristics of MENs is their ability to deliver
drugs specifically into the cancer cells without affecting the
surrounding normal cells. The penetration fields due to the
nanoelectroporation, i.e., the mechanism according to which
the delivery takes place, are different for the two cell forms,
i.e., cancer and normal cells, respectively, because their
membranes have different surface morphologies and charge
configurations, as shown through transport measurements
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and AFM studies. As a result, it takes a significantly higher
field to break the dielectric barrier of the normal cell membranes compared to that of the cancer cells. As mentioned
above, it is well known that even at the macroscale, the cancer cells have a smaller threshold field for the electroporation
compared to their normal counterparts; the difference is a
factor of two to five depending on the cancer type. The discussed experiments with MENs have shown that at the nanoscale the difference becomes even more significant. For
example, for the ovarian and normal cancer cell lines,
SKOV-3 and HOMEC, respectively, it takes less than
100 Oe and significantly more than 1000 Oe, respectively, to
induce the nanoelectroporation via the ME effect. That is the
reason why we refer to the electroporation (by MENs) at the
nanoscale as the nanoelectroporation. The nanoelectroporation seems to have a significantly higher specificity factor
compared to the traditional electroporation effect which
takes place at the macroscale. The AFM imaging of equivalent glioblastoma cancer and normal endothelial cells has
shown very different surface topographies for the two cell
types; the normal cells are more continuous compared to the
cancer cells which in turn have visible striations of the characteristic size on the order of 100 nm. The AFM images have
also shown that 30-nm MENs tend to accumulate in these
striations and thus penetrate the cell through these striations.
The fact that the nanoparticles penetrate the cancer cells
through the small striations in the membrane might explain
why the ratio between the nanoelectroporation threshold
fields between cancer and normal cells is more significant
(ⲏ10) compared to that for the traditional electroporation at
the macroscale (2–5). It is worth noting that due to the
intrinsic nature of the ME coupling in the multiferroic nanostructures, the magnetic field strength on the order of
100 Oe, required for enabling the high-specificity delivery
and release functions, is substantially below any harmful
limits as per US Food and Drug Administration (FDA) regulations.78 Eventually, because of the fundamental nature of
this approach, it can be applied to any cancer type. Last but
not least, it can be mentioned that most current studies have
been performed with MENs of the same coreshell composition, i.e., CoFe2O4–BaTiO3. These experiments have been
vital to demonstrate the feasibility of the MEN-based cancer
treatment approaches. In the future, other compositions can
be explored, e.g., ones made of biodegradable organic
materials.
V. MATERIALS AND PROCEDURES
A. Chemical synthesis of MENs

FIG. 8. AFM image pair (z height and phase (right)) for glioblastoma cells
with MENs found in striations on the surface membrane. The observed
nanoparticles are approximately 30-nm in diameter.

CoFe2O4-BaTiO3 core shell MENs were prepared
according to a polyvinylpyrrolidone assisted hydrothermal
method. First, 0.058 g of Cobalt Nitrate Hexahydrate
(Co(NO3)26H20) and 0.16 g of Ferric Nitrate Nonahydrate
(Fe(NO3)39H20) were dissolved by stirring in 15 ml of distilled water. Polyvinylpyrrolidone (PVP), 0.2 g, was dissolved in 5 ml of aqueous solution containing 0.9 g of
sodium borohydride. The PVP-sodium borohydride solution
was added dropwise to the above solution and the mixture
was stirred at 120  C until the liquid phase evaporated.
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CoFe2O4 particles were recovered, dispersed in distilled
water through sonication, and washed 3 times using magnetic separation. Purified CoFe2O4 cores were dried at
120  C for 24 h and stored at room temperature until further
use. The Barium Titanate (BaTiO3) shell was prepared using
the citrate gel method. Briefly, CoFe2O4 cores were dispersed in distilled water through sonication. Barium
Carbonate (BaCO3), 174 mg, was dissolved in 60 ml deionized water containing 1 g of citric acid. This solution was
mixed with a 150 ml ethanolic solution of titanium (IV) isopropoxide (284 ll) and 6 g citric acid. The BaTi precursor
solution was added to the cores and sonicated at room temperature for 1 h. The translucent yellow liquid was stirred at
70  C until the liquid phase evaporated completely. Finally,
the gel was calcined at various temperatures ranging from
500 to 800  C (CMF-1100) for 5 h and cooled naturally to
room temperature. The gelation temperature and the final
temperature were important determinants of the crystal structure and the final size of CoFe2O4-BaTiO3 core shell MENs.
For example, a temperature of 600  C was required for 30nm MENs.
B. Vibrating sample magnetometry

A cryogen-free 9-T vibrating sample magnetometer
(VSM) physical property management system from
Quantum Design was used to measure M-H loops and M-T
dependence in a temperature ranging from 1.9 to 400 K.
C. Transmission electron microscopy (TEM)

A Phillips CM-200 200 kV Transmission Electron
Microscope (TEM) with an Energy Dispersive Spectroscopy
(EDS) option was used to obtain TEM images and EDS
profiles.
D. Atomic force microscopy

The imaging of both glioblastoma and brain endothelia
cells in a cellular microenvironment was conducted using a
MultiMode AFM system. Using a Bruker electrochemistry
fluid cell probe holder that has an integrated piezo element
for contact mode experiments and Bruker’s DNP-S10 silicon nitride probe, we were able to achieve the desired
results showing the interaction between MENs and the surface of a cell. The DNP-S10 probe comes with four different cantilevers of various dimensions each having a
different nominal spring constant value and resonant frequency. The special C triangular shape cantilever was used
for cell imaging; the cantilever has a nominal resonant frequency of 56 kHz and a nominal spring constant of 0.24N/
m which are ideal values for imaging stiff and firmly
attached samples. After placing the probe in the liquid solution, which for this experiment was phosphate buffer solution (PBS), the resonant frequency dropped to 8 kHz, i.e.,
an order of magnitude lower compared to the frequency in
air. After obtaining a lower resonant frequency, the probe
was engaged with the membrane surface for scanning at a
frequency rate of 0.100 Hz and a scan size of 100 nm; these
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two parameters were gradually increased until an adequate
quality image was obtained.
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